dc.contributor.authorJain, Mukul R.
dc.contributor.authorGiri, Suresh R.
dc.contributor.authorBhoi, Bibhuti
dc.contributor.authorTrivedi, Chitrang
dc.contributor.authorRath, Akshyaya
dc.contributor.authorRathod, Rohan
dc.contributor.authorRanvir, Ramchandra
dc.contributor.authorKadam, Shekhar
dc.contributor.authorPatel, Hiren
dc.contributor.authorSwain, Prabodha
dc.contributor.authorRoy, Sib Sankar
dc.contributor.authorDas, Nabanita
dc.contributor.authorKarmakar, Eshani
dc.contributor.authorWahli, Walter
dc.contributor.authorPatel, Pankaj R.
dc.identifier.citationJain, M. R., Giri, S. R., Bhoi, B., Trivedi, C., Rath, A., Rathod, R., . . . Patel, P. R. (2018). Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models. Liver International, 38(6), 1084-1094. doi:10.1111/liv.13634en_US
dc.description.abstractBackground & Aims: Non‐alcoholic fatty liver disease (NAFLD) and non‐alcoholic steatohepatitis (NASH) are common clinico‐pathological conditions that affect millions of patients worldwide. In this study, the efficacy of saroglitazar, a novel PPARα/γ agonist, was assessed in models of NAFLD/NASH. Methods & Results: HepG2 cells treated with palmitic acid (PA;0.75 mM) showed decreased expression of various antioxidant biomarkers (SOD1, SOD2, glutathione peroxidase and catalase) and increased expression of inflammatory markers (TNFα, IL1β and IL6). These effects were blocked by saroglitazar, pioglitazone and fenofibrate (all tested at 10μM concentration). Furthermore, these agents reversed PA‐mediated changes in mitochondrial dysfunction, ATP production, NFkB phosphorylation and stellate cell activation in HepG2 and HepG2‐LX2 Coculture studies. In mice with choline‐deficient high‐fat diet‐induced NASH, saroglitazar reduced hepatic steatosis, inflammation, ballooning and prevented development of fibrosis. It also reduced serum alanine aminotransferase, aspartate aminotransferase and expression of inflammatory and fibrosis biomarkers. In this model, the reduction in the overall NAFLD activity score by saroglitazar (3 mg/kg) was significantly more prominent than pioglitazone (25 mg/kg) and fenofibrate (100 mg/kg). Pioglitazone and fenofibrate did not show any improvement in steatosis, but partially improved inflammation and liver function. Antifibrotic effect of saroglitazar (4 mg/kg) was also observed in carbon tetrachloride‐induced fibrosis model. Conclusions: Saroglitazar, a dual PPARα/γ agonist with predominant PPARα activity, shows an overall improvement in NASH. The effects of saroglitazar appear better than pure PPARα agonist, fenofibrate and PPARγ agonist pioglitazone.en_US
dc.format.extent11 p.en_US
dc.relation.ispartofseriesLiver Internationalen_US
dc.rights© 2017 Cadila Healthcare Ltd., Liver International Published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.en_US
dc.subjectDual‐PPAR Agonisten_US
dc.titleDual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH modelsen_US
dc.typeJournal Article
dc.contributor.schoolLee Kong Chian School of Medicine (LKCMedicine)en_US
dc.description.versionPublished versionen_US

Files in this item


This item appears in the following Collection(s)

Show simple item record